Exon 20 insertions in NSCLC - ESMO 2020

Bookmark and Share
Published: 25 Sep 2020
Views: 1749
Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro

Dr Alex Spira, Prof Benjamin Besse, Dr Antonio Passaro and Prof Michael Thomas discuss the state of play for the treatment of non small cell lung cancer expressing exon 20 EGFR mutations.

Unlike EGFR L858R point mutation or exon 19 deletions, which represent the majority of EGFR mutations in NSCLC, low frequency EGFR exon 20 insertion mutations are associated with de novo resistance to targeted EGFR inhibitors and correlate with a poor patient prognosis.

The panel discuss challenges in treatment, their current practice, novel therapies and look towards the future for this hard to tackle cancer.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).